Table 2. Characteristics of patients with metachronous breast and ovarian malignancies who underwent BRCA1/2 testing.
| Characteristic | Entire cohort (n=18) | BRCAm (n=7) | BRCAw (n=11) | p-value | |
|---|---|---|---|---|---|
| Median age (yr)* | 47.8 (31.6–68.0) | 43.9 (31.6–55.8) | 48.3 (32.7–68.0) | 0.439 | |
| FIGO stage (OV) | 0.335 | ||||
| I–II | 9 (50.0) | 2 (28.6) | 7 (63.6) | ||
| III–IV | 9 (50.0) | 5 (71.4) | 4 (36.4) | ||
| Histology (OV) | <0.001 | ||||
| Serous adenocarcinoma | 8 (44.4) | 7 (100) | 1 (9.1) | ||
| Clear cell adenocarcinoma | 7 (38.9) | 0 (0) | 7 (63.6) | ||
| Endometrioid adenocarcinoma | 3 (16.7) | 0 (0) | 3 (27.3) | ||
| Mucinous adenocarcinoma | 0 | 0 | 0 | ||
| Differentiation (OV) | 0.685 | ||||
| Well-differentiated | 1 (5.6) | 0 (0) | 1 (9.1) | ||
| Moderately-differentiated | 2 (11.1) | 0 (0) | 2 (18.2) | ||
| Poorly-differentiated | 15 (83.3) | 7 (100) | 8 (72.7) | ||
| Receptor status (BR) | 0.892 | ||||
| ER− and PR− | 5 (29.4) | 2 (28.6) | 3 (30.0) | ||
| ER and/or PR+ | 7 (41.2) | 2 (28.6) | 5 (50.0) | ||
| HER2+ | 3 (17.6) | 2 (28.6) | 1 (10.0) | ||
| ER+, PR+, and HER2+ | 2 (11.8) | 1 (14.3) | 1 (10.0) | ||
| Order of cancer diagnosis | >0.999 | ||||
| BR− > OV | 7 (38.9) | 3 (42.9) | 4 (36.4) | ||
| OV− > BR | 11 (61.1) | 4 (57.1) | 7 (63.6) | ||
| BR− > OV (yr) | 2.7 (0.6–13.4) | 11.8 (1.0–13.4) | 1.8 (0.6–8.0) | 0.229 | |
| OV− > BR (yr) | 1.8 (0.3–9.2) | 2.5 (0.3–7.7) | 1.8 (1.2–9.2) | 0.648 | |
Values are presented as number (range) or number (%).
BR, breast cancer; BRCAm, BRCA1/2 mutant; BRCAw, BRCA1/2 wild-type; FIGO, International Federation of Gynecology and Obstetrics; ER, estrogen receptor; OV, ovarian cancer; PR, progesterone receptor.
*Age at first cancer diagnosis.